The precision cancer therapy developer, which counts Sanofi as a significant shareholder, floated at the top of an upsized range and saw its price continue to rise post-IPO.

US-based cancer therapy developer Revolution Medicines raised $238m yesterday in an initial public offering on the Nasdaq Global Market that scored an exit for pharmaceutical company Sanofi. The company priced its shares at the top of a $15 to $17 range that had been upsized from the IPO’s original $14 to $16 range, set last…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.